ZYAMIS (Veriton Pharma Pty Limited)
Product name
ZYAMIS
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
194 (255 working days)
Active ingredients
midazolam maleate
Registration type
EOI
Indication
ZYAMIS (oromucosal solution), as buccal midazolam, is indicated for the treatment of generalised convulsive status epilepticus (GCSE), in those over 6 months old.